Total Funding
85
60
Total FundingSeries A raised
Growth Score
-6 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
10166
Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases.
- Rahul Dhanda: Co-Founder, President, Chief Executive OfficerPast Role: Sherlock Biosciences, Strategic Advisor, Co-founder, and Founding CEO
Giovanni Traverso: Co-Founder
About the Company
Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. Its oral therapies harness the small intestine’s biology to provide more
accessible, effective, and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. It is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body’s nexus for metabolic control, digestion, and drug absorption.
